SNGX News and Press, Soligenix Inc. From 11/08/21

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom PR Newswire PRINCETON, N.J. , Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical com...

Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine - Vaccinated mice remained protected against lethal ricin poisoning for at least 12 months post-vaccination - Strong protection mounted within 1 month of vaccination and...

Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development PR Newswire PRINCETON, N.J. , Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a ...

Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines New York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNG...

HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit HyBryte™ filling a Critical Need in the CTCL Treatment Landscape PR Newswire ...

COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants New York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and administering COVID-19 vaccines that need to be stored at sub-zero temperatures is hampering...

Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates - Vaccination yields broad neutralizing antibody responses against original strain and Beta, Gamma and Delta variants - Durable re...

Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference Live fireside chat with Dr. Christopher J. Schaber, President and Chief Executive Officer of Soligenix on Wednesday, September 29 at 8:00 AM ET PR Newswire PRINCETON, N.J. , Sept...

Soligenix to Advance Synthetic Hypericin Development in Psoriasis - Validated clinical pharmacology and positive psoriasis proof-of-concept clinical study with synthetic hypericin sets stage for pipeline expansion - Plan to initiate follow-on Phase 2a clinical study in mild-...

Soligenix discusses its contribution to addressing future serious public health threats in a podcast New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has already cost the United States an estimated $16 trillion in lost economic output , and has...